

Technological Innovations in Type 1 Diabetes Mellitus Management: A Narrative Review

Gunañilake S. S. C¹

¹ Diabetes and Endocrine Unit, National Hospital, Kandy, Sri Lanka

Abstract

Type 1 Diabetes Mellitus (T1DM) presents significant challenges in management due to its complex nature and potential complications. Technological innovations have revolutionized T1DM care, offering novel solutions to improve glycemic control, enhance quality of life, and mitigate the risk of complications. This comprehensive review explores the latest advancements in T1DM management, including continuous glucose monitoring (CGM) systems, closed-loop insulin delivery systems, connected insulin pens, smartphone applications, and digital healthcare platforms. These innovations provide real-time feedback, automate insulin delivery, facilitate remote monitoring, and empower individuals to take proactive control of their diabetes management. The review discusses the benefits, challenges, and implications of these technologies in optimizing T1DM care and improving patient outcomes.

Keywords: T1DM, Technology, Continuous Glucose Monitoring (CGM), Insulin pump, Time in Range (TIR) Closed-Loop insulin delivery system, Digital health care platforms

Correspondence email: sonaligunañilake@gmail.com

ORCID ID: <https://orcid.org/0000-0003-0636-350X>

Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (CC BY 4.0)

Introduction

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition characterized by the destruction of pancreatic beta cells, leading to insulin deficiency and subsequent dysregulation of blood glucose levels. The management of T1DM poses significant challenges to individuals and healthcare providers due to its complex nature and potential complications. Globally, T1DM affects millions of individuals, with varying prevalence rates among different populations. Recent review of world prevalence suggested 9.5% of all individuals with diabetes worldwide are attributed to T1DM [1]. The incidence of T1DM is increasing globally, particularly among children and adolescents, with projections suggesting a continued rise in prevalence in the coming decades [2]. This increasing prevalence places a significant burden on healthcare systems and individuals, highlighting the urgent need for effective management strategies.

Advancements in technology have revolutionized the landscape of T1DM management, offering novel solutions to improve glycemic control, enhance quality of life, and mitigate the risk of acute and chronic complications and improving the quality of life for individuals living with the condition [3].

This comprehensive review aims to explore the latest technological innovations in T1DM management, encompassing a range of devices and systems designed to monitor glucose levels, administer insulin, and provide personalized therapeutic interventions.

Technological innovations:

Technological innovations in T1DM may range from advanced devices for monitoring of glycemic levels to smart delivery of insulin. Continuous glucose monitoring systems, closed-loop systems, insulin delivery devices, and mobile health applications are among the innovative technologies transforming T1DM care [4-6]. These advancements provide real-time feedback, automate insulin delivery, facilitate remote monitoring, and empower individuals to take proactive control of their diabetes management, reducing the burden of constant monitoring and enabling more personalized treatment approaches. The rapid pace of innovation in this field continues to promise further enhancements in precision, effectiveness, and user-friendliness, ultimately leading to better outcomes for those living with type 1 diabetes.

Monitoring Glycemic Levels

Continuous Glucose Monitoring systems

Continuous glucose monitoring (CGM) devices play a crucial role in diabetes management by providing real-time data on glucose levels, allowing for more precise insulin dosing and lifestyle adjustments. These devices typically consist of a subcutaneously inserted enzymatic or fluorescent based sensor that measures interstitial glucose levels, a transmitter that wirelessly sends data to a receiver or smartphone app, and software for data analysis and display (Figure 1). Although the systems measure glucose concentrations in the interstitial fluid, algorithms are used to predict the blood glucose levels which will be presented as the output. Two types of CGM systems, intermittent scanned CGM (isCGM or flash glucose monitoring systems) and real-time (rtCGM) CGM, offer distinct functionalities. isCGM systems require users to scan the sensor to obtain glucose readings intermittently, while rtCGM systems provide continuous real-time glucose data without the need for scanning. Over time, CGM technology has advanced significantly, with improvements in accuracy, sensor longevity, and user interface. Modern CGM systems often incorporate customizable alarm systems to alert users to hypo- and hyperglycemic excursions, impending hypoglycemia, or rapidly changing glucose trends, enhancing safety and peace of mind for individuals with diabetes [4, 7].

Novel inventions like implantable Continuous Glucose Monitoring (CGM) systems, like the Eversense CGM System, are subcutaneously placed devices providing long-term glucose monitoring with minimal user intervention, particularly suitable for individuals seeking extended glucose monitoring without frequent sensor replacements and may offer benefits for individuals who prefer not to wear external sensors continuously. [7]. Moreover, integration with insulin delivery systems, such as insulin pumps, has facilitated the development of closed-loop systems or artificial pancreas systems, which automate insulin delivery based on real-time glucose readings, further optimizing glycemic control [5].

Indications for CGM use include suboptimal glycemic control despite conventional glucose monitoring methods, hypoglycemia unawareness, frequent hypoglycemic episodes, and a need for tighter glycemic control in pregnancy or specific clinical scenarios. While CGM devices offer numerous advantages, including improved glycemic

control, reduced risk of hypoglycemia, and enhanced quality of life, they also have limitations such as cost, potential inaccuracies requiring calibration and proper insertion, skin irritation, and technical issues like sensor errors or signal loss [6]. Users may become overly reliant on CGM data, leading to neglect of other management aspects, and on the other hand, some experience alarm fatigue, burden with too much of information on glycemic fluctuations and have concerns regarding privacy and data security.

Time In Range measurement

Using the technological advancement, novel approach in diabetes management offers real-time insights in to glycemic control by quantifying the percentage of time spent within, above, and below target glucose ranges, typically set between 70 mg/dL (3.9 mmol/L) and 180 mg/dL (10.0 mmol/L), Time in Range (TIR) measurement. Calculated using CGM or flash glucose monitoring systems, TIR provides a comprehensive understanding of glycemic variability, guiding treatment decisions in real time. Accepted TIR percentages include above-target (>180 mg/dL) and below-target (<70 mg/dL) thresholds, with recommended targets of >70-80% within range, <4% below range, and <25% above range [7, 8].

Scientific evidence supports the superiority of TIR over HbA1c in assessing glycemic control due to reflection of glycemic variability, higher correlations with mean Glucose levels, real-time guidance for treatment, and alignment with patient-centered outcomes [7, 9-11]. Clinical trials, systematic reviews, and real-world data consistently demonstrate the superior benefits of continuous glucose monitoring compared to self-monitoring of blood glucose (SMBG) in managing diabetes. CGM leads to significant reductions in HbA1c levels, aiding in glycemic control over time [12]. Moreover, CGM technology has shown efficacy in preventing hypoglycemic & hyperglycemic emergencies, thereby enhancing patient safety [13]. Additionally, CGM has been found to improve hypoglycemia unawareness, a critical aspect in diabetes management, by providing real-time glucose readings and alerts [14].

However, challenges associated with TIR measurement include variability in device accuracy, interpretation of data, and standardization of target ranges across different populations and clinical settings [15]. Nonetheless, CGM/TIR presents a valuable complement to traditional glycemic assessments, aiding in optimizing glycemic outcomes and reducing diabetes-related complications.




Figure 1 : Continuous glucose monitoring system. **A.** Components of CGM system; **B.** CGM report with details on glycemic levels and patterns.

Picture adopted from -Judge C. Interpreting CGM data. *Australian Diabetes Educator*. 2020;23(2). Freckmann G. Continuous glucose monitoring (CGM) in diabetes therapy. *Medizinische Monatsschrift für Pharmazeuten*. 2020; 41:455-60

Table 1: Characteristics of CGMs

CGM Device	Dexcom G6	Dexcom G7	Guardian Sensor 3	Guardian Sensor 4	Eversense	Eversense E3	FreeStyle Libre 2	FreeStyle Libre 3
Company	Dexcom	Dexcom	Medtronic	Medtronic	Senseonics	Senseonics	Abbott	Abbott
FDA Approval	2018	2022	2018	2023	2018	2022	2020	2022
Approved ages	≥ 2 years	≥ 2 years + Pregnancy	>3 years	>7 years	> 18 years	> 18 years	> 4 years + Pregnancy	>4 years + Pregnancy
Location for placement	Abdomen, Back of upper arm	Back of Upper arm	Back of upper arm, abdomen	Back of upper arm, abdomen	Back of upper arm	Back of upper arm	Back of Upper arm	Back of Upper arm
Sensor type	Real-time Readings sent to receiver/smart device every 5 mins	Real-time Readings sent to receiver/smart device every 5 mins	Real-time Readings sent to smart device every 5 mins	Real-time Readings sent to smart device every 5 mins	Real-time Readings sent to smart device every 5 mins	Real-time Readings sent to smart device every 5 mins	Scanning required only when starting a new sensor Readings sent to reader/smart device Measures every min. Records every 15min	Real time Readings sent to reader/smart device Measures every min. Records every 15min
Wear Time	10 days	10 days	7 days	10 days	90 days	180 days	14 days	14 days
Calibration	None	None	2/day	1 /day	None	None	None	None
Alarms for Hyper / Hypo	Yes	Yes	Yes	Yes	Yes – on body vibration	Yes – on body vibration	Yes	Yes
Platform	Dexcom	Dexcom	CareLink	CareLine			LibreView	LibreView
Bluetooth Free Range	6 m	6 m	6 m	6 m	7.6m	7.6m	NA	10m
Interferences	Hydroxyurea Acetaminophen (> 1g qds for adults)	Hydroxyurea Acetaminophen (> 1g qds for adults)	Acetaminophen	Not known	Antibiotics of tetracycline class	Antibiotics of tetracycline class	Ascorbic acid	Ascorbic acid
Insulin pump integration	Tandem t:slim X2 Omnipod 5	Tandem t:slim X2 Beta bionics iLet	MiniMed 630G, 770G	MiniMed 780G	None	None	For Libre 2Plus – Tandem t:slim X2, Omnipod 5	Await




Figure 2:Hybrid close loop insulin pump system / Close loop insulin pump system. **A.** Components of insulin pump. **B.** Hybrid close loop insulin pump system

Picture adopted from Kollman P, Burke E. *Current and Emerging Technologies for the Diagnosis and Treatment of Diabetes Mellitus. Current Emergency and Hospital Medicine Reports.* 2024;12:1-12. Valla V. *Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps. Experimental diabetes research.* 2010;2010:178372.

Insulin Delivery Systems

Insulin Pumps

Insulin pumps represent a cornerstone in diabetes management, offering a continuous and precise method of insulin delivery for individuals with T1DM. These devices work by delivering rapid-acting insulin subcutaneously through a cannula, mimicking the physiological secretion of insulin more closely than traditional injection-based regimens. Insulin pumps typically consist of a pump reservoir containing insulin, a tubing system connected to a subcutaneous infusion set, and a programmable interface for setting basal rates of rapid-acting insulin and administering bolus doses (Figure 2) [16]. There are two types of pumps, tethered pumps (using a fine tube system to connect the pump in to the cannula placed subcutaneously) and patch pumps (there is no tubing or very short tube, where pump is stuck on to the skin). Pumps work by continuously delivering basal rate of insulin at predetermined rates throughout the day to maintain stable blood glucose levels between meals and overnight [5]. Additionally, users can administer bolus doses of insulin to cover meals or correct elevated glucose levels.

This technology allows for more precise insulin dosing and flexibility in managing insulin requirements, particularly for individuals with variable insulin needs or those requiring small insulin increments. In addition, insulin pumps offer convenience and discretion, as they eliminate the need for multiple daily injections.

Indications for insulin pump therapy include suboptimal glycemic control with multiple daily injections, frequent hypoglycemia, variable insulin requirements, and a desire for greater flexibility in insulin dosing [17]. Scientific evidence supports the efficacy of insulin pump therapy in improving glycemic control, reducing HbA1c levels, and minimizing the risk of hypoglycemia [18].

Additionally, studies have shown that insulin pump therapy is associated with greater patient satisfaction, improved quality of life, and increased treatment adherence compared to injection-based regimens [11]. However, challenges such as technical issues, infusion site problems, and the learning curve associated with pump therapy may impact patient acceptance and adherence. However, disadvantages include the risk of pump malfunction, infusion site complications (such as infection or irritation), and the cost of pump supplies and maintenance [19].

Recent technological advancements in insulin pump technology focus on enhancing user experience, improving device accuracy and reliability, and expanding integration with other diabetes management technologies. These advancements include smaller and more discreet pump designs, improved infusion sets with extended wear times, integration with smartphone applications for remote monitoring and control, and integration of CGM / development of closed-loop or hybrid closed-loop systems for automated insulin delivery based on real-time CGM data (Table 2) [5].

Hybrid and closed-Loop insulin delivery system

Hybrid and closed-loop insulin delivery systems represent significant advancements in diabetes management, offering automated insulin delivery based on real-time glucose data. Hybrid systems, also known as predictive low glucose suspend systems, combine CGM with insulin pump therapy to adjust insulin delivery in response to predicted glucose trends, particularly hypoglycemia. These systems utilize algorithms to anticipate impending hypoglycemia and suspend insulin delivery temporarily, thereby mitigating the risk of severe hypoglycemic events while maintaining glycemic control (Figure 2) [20]. However, the user still needs to manually administer bolus insulin doses for meals and adjust basal insulin rates as needed. Essentially, the system provides automated adjustments to basal

Table 2: Overview of the distinctions between the different types of pump systems

Type	Description	Features
Continuous Subcutaneous Insulin Infusion (CSII) - Pump Therapy	Uses an insulin pump to deliver insulin continuously throughout the day.	- Continuous insulin delivery - User-adjustable basal rates and bolus doses - Requires manual glucose monitoring
Sensor-Augmented Pump Therapy (SAP)	Combines pump therapy with CGM systems.	- Real-time glucose monitoring (CGM) integration with insulin pump - Predictive low glucose suspend function through connection to rtCGM - Reduced risk of hypoglycemia and hyperglycemia
Hybrid Closed-Loop Systems	Integrates insulin pump, CGM sensor, and control algorithm for automatic adjustments of insulin delivery.	- Automated basal insulin adjustments - Requires user input for meals time insulin bolus dose - Improved glucose control
Closed-Loop Systems	Fully automated insulin delivery systems that mimic the function of a healthy pancreas.	- Automated basal and bolus insulin adjustments (independent artificial pancreas) - Minimal user intervention required - Optimal glucose control

insulin rates to maintain glucose levels within target ranges, but the user remains involved in insulin dosing decisions.

Closed-loop insulin delivery systems, also known as artificial pancreas systems, provide fully automated insulin delivery by integrating CGM with insulin pump therapy and sophisticated control algorithms without requiring user intervention for insulin dosing decisions. These systems continuously monitor glucose levels and adjust insulin delivery rates in real-time to maintain glucose within target ranges, mimicking the physiological function of the pancreas more closely [5, 21].

Indications for hybrid and closed-loop insulin delivery systems include suboptimal glycemic control with conventional insulin therapy, frequent hypoglycemia, impaired awareness of hypoglycemia, and a desire for greater automation and flexibility in insulin management. It is known to have higher efficacy in improving glycemic control, reducing HbA1c levels, and minimizing the risk of hypoglycemia compared to conventional insulin therapy [22]. Additionally, studies have demonstrated improved quality of life, and increased treatment adherence with hybrid and closed-loop insulin delivery systems, attributed to reduced diabetes-related stress and burden [20]. However, challenges such as cost, technical issues, and the need for ongoing user education and support remain important considerations.

Several trials have demonstrated the efficacy of hybrid closed-loop insulin pumps (HCLP) and closed-loop insulin pumps (CLP) in improving HbA1c levels for individuals with diabetes. The "International Diabetes Closed-Loop" (IDCL) trial [23] showcased a mean HbA1c reduction of approximately 0.3% to 0.5% with HCLP systems compared to baseline, while the PROLOG trial [24] also reported similar findings. Likewise, pivotal trials such as the Diabeloop [25] and CamAPS FX [25] trials evidenced significant reductions in HbA1c levels with CLP systems, with the Diabeloop trial indicating a mean HbA1c decrease of approximately 0.6% compared to baseline. These findings underscore the efficacy of both HCLP and CLP systems in enhancing glycemic control and highlight their potential to mitigate the burden of diabetes-related complications.

Recent advancements in hybrid and closed-loop insulin delivery systems focus on improving algorithm accuracy, enhancing user experience, and expanding compatibility with other diabetes management technologies [27]. Further research is ongoing on dual hormone (insulin + glucagon) closed loop delivery systems to reduce hypoglycemic events and for better overall glycemic levels.

Advancing the field of diabetes technology faces numerous challenges, including ensuring accuracy and reliability, integrating different components seamlessly, addressing cost and accessibility barriers, enhancing user experience and acceptance, and navigating regulatory and reimbursement hurdles. While diabetes technology has significantly improved glucose management and quality of life for individuals with type 1 diabetes, it may not offer a

"perfect cure" on its own, as addressing the underlying autoimmune process remains crucial. Peripheral insulin delivery aims to mimic physiological insulin secretion but faces challenges in achieving precise mimicry and balancing multiple hormones.

Connected Insulin Pen

Connected insulin pens (CIP) are innovative devices that integrate wireless connectivity features, such as Bluetooth or Near Field Communication (NFC), to enable real-time data transmission of insulin dosing information to smartphone applications or cloud-based platforms. These pens automatically capture and transmit data on insulin doses, including dose timing, dose size, and injection site, offering users and healthcare providers valuable insights into insulin dosing patterns and treatment adherence. Scientific evidence supports the efficacy and benefits of connected insulin pens in improving diabetes management outcomes.

Several studies have demonstrated the effectiveness of connected insulin pens in enhancing treatment adherence and glycemic control. For example, a study by Lajara et al. (2020) showed that patients using connected insulin pens achieved greater improvements in HbA1c levels compared to those using traditional insulin pens, with increased adherence to insulin therapy [28]. Similarly, a real-world evidence study by Reutrakul and Chirakalwasan (2021) found that patients using connected insulin pens experienced significant reductions in HbA1c levels and improved treatment satisfaction compared to baseline [29]. These findings highlight the potential of connected insulin pens to positively impact glycemic outcomes and patient experiences in diabetes management.

In addition to improving treatment adherence and glycemic control, connected insulin pens offer other benefits, such as enhanced convenience, data transparency, and communication between patients and healthcare providers. By providing real-time access to insulin dosing information and trends, connected insulin pens empower users to make informed decisions about their diabetes management and facilitate collaborative care with healthcare professionals. Furthermore, connected insulin pens streamline data collection and analysis, enabling more personalized and proactive adjustments to insulin therapy to optimize treatment outcomes.

Digital Health Applications

Smart phone applications

Smartphone applications have emerged as valuable tools in advancing T1DM care, offering a wide range of functionalities to help individuals manage their condition effectively. These applications leverage the ubiquitous presence of smartphones to provide convenient, accessible, and personalized support for various aspects of diabetes management, including glucose monitoring, insulin dosing, carb counting and meal planning, physical activity tracking, and data analysis.

One of the key features of smartphone applications in T1DM care is glucose monitoring, with many

applications allowing users to input and track blood glucose levels manually or sync with CGM systems for real-time data visualization and analysis. Studies have shown that smartphone-based glucose monitoring applications can improve glycemic control by providing users with timely insights into their glucose trends and patterns, enabling proactive adjustments to insulin dosing and lifestyle factors [30].

Smartphone applications also offer functionalities for insulin dosing calculation and management, facilitating more accurate and convenient insulin administration for individuals with T1DM. These applications often include insulin dose calculators, bolus dose recommendations based on carbohydrate intake and blood glucose levels, and dose tracking features to monitor insulin usage over time. Research has demonstrated the effectiveness of smartphone-based insulin dosing applications in improving treatment adherence and glycemic outcomes in individuals with T1DM [31].

In addition to glucose monitoring and insulin dosing support, smartphone applications for T1DM care offer various tools and resources for meal planning, physical activity tracking, medication management, and data analysis. These applications may include features such as carbohydrate counting databases, meal logging functionality, exercise tracking, medication reminders, and data visualization tools to help users better understand and manage their diabetes. Studies have highlighted the positive impact of smartphone applications on diabetes self-management behaviors, treatment adherence, and overall quality of life for individuals with T1DM [32].

Furthermore, smartphone applications enable seamless communication and data sharing between individuals with T1DM and their healthcare providers, facilitating remote monitoring, telemedicine consultations, and collaborative care. By allowing users to share glucose data, insulin dosing records, and other relevant information with their healthcare team in real-time, smartphone applications empower individuals with T1DM to receive timely feedback, support, and guidance for optimizing their diabetes management.

Digital health care platforms and Artificial Intelligence

Digital healthcare platforms and artificial intelligence (AI) have emerged as groundbreaking technological innovations in the management of T1DM, offering personalized and data-driven approaches to optimize patient care and outcomes. These platforms leverage the power of technology, data analytics, and machine learning algorithms to provide comprehensive support for various aspects of diabetes management, including glucose monitoring, insulin dosing, lifestyle interventions, and patient education.

One of the key features of digital healthcare platforms in T1DM management is their ability to integrate data from multiple sources, such as CGM systems, insulin pumps, smart insulin pens, wearable devices, and patient-reported data, into a unified platform for real-time monitoring and analysis. By aggregating and analyzing this data using AI-driven

algorithms, digital healthcare platforms can generate actionable insights into patients' glucose trends, patterns, and treatment responses, enabling personalized recommendations for insulin dosing adjustments, meal planning, physical activity, and other lifestyle modifications [33].

Furthermore, AI-powered predictive analytics models have the potential to anticipate future glucose fluctuations and identify risk factors for hypoglycemia and hyperglycemia, allowing for proactive interventions to prevent adverse events and optimize glycemic control. These models leverage machine learning algorithms trained on large datasets of patient-specific glucose data to predict individualized glucose trajectories and guide clinical decision-making in real-time. Studies have demonstrated the effectiveness of AI-based predictive analytics in improving glycemic outcomes and reducing the incidence of hypoglycemia in individuals with T1DM [34]. Further, advances in machine learning and predictive analytics have facilitated the development of prediction models and risk stratification tools to identify individuals at high risk of developing T1DM. These models integrate genetic, immunological, clinical, and environmental factors to assess the likelihood of T1DM development and enable targeted interventions, such as immune modulation therapies or intensive monitoring, in high-risk populations [35].

In addition to glucose monitoring and predictive analytics, digital healthcare platforms offer various tools and resources for patient education, self-management support, and remote monitoring. These platforms may include features such as interactive educational modules, virtual coaching programs, peer support networks, and telemedicine consultations to empower patients with knowledge, skills, and resources for better diabetes self-care. Research has shown that digital healthcare platforms can enhance patient engagement, treatment adherence, and quality of life for individuals with T1DM, leading to improved clinical outcomes and reduced healthcare costs [36].

Moreover, digital healthcare platforms facilitate seamless communication and collaboration between patients, caregivers, and healthcare providers, enabling remote monitoring, telemedicine consultations, and coordinated care delivery. By providing real-time access to patient data, AI-driven insights, and decision support tools, these platforms empower healthcare teams to deliver personalized, proactive, and evidence-based care to individuals with T1DM, thereby improving clinical outcomes, patient satisfaction, and overall healthcare efficiency.

Diabetes technology in the developing world

In the forefront of diabetes care, developed countries have witnessed remarkable advancements in T1DM technology. CGMs, insulin pumps, and closed-loop systems have transformed management strategies, offering unparalleled precision, fewer hypoglycemic events, and an elevated quality of life for those living with type 1 diabetes. Yet, despite these triumphs, the landscape of diabetes technology in developing countries, particularly in South Asian regions,

presents a vastly different picture. Here, the journey toward implementing such innovations encounters a labyrinth of challenges, from financial constraints and limited prevalence to barriers in health literacy, technological familiarity, and linguistic diversity. Overcoming these hurdles demands tailored solutions that address socioeconomic and cultural contexts, focusing on affordability, enhancing literacy, facilitating technology financially as well through exchange of knowledge and providing support in local languages. Collaboration among various stakeholders is crucial for ensuring equitable access to diabetes technology and improving outcomes in developing countries and South Asian regions.

In the era of diabetes technology, the role of type 1 diabetes self-management education (DSME) remains pivotal. While technological advancements have revolutionized glucose monitoring and insulin delivery, DSME provides the foundational knowledge and skills necessary for individuals to effectively utilize these tools. DSME empowers individuals with type 1 diabetes to understand their condition, make informed decisions about treatment options, and navigate the complexities of diabetes management. It teaches essential concepts such as carbohydrate counting, insulin dosing, and interpreting glucose data from CGMs and other devices. Moreover, DSME fosters problem-solving abilities and encourages proactive self-care behaviors, enabling individuals to optimize their glycemic control and minimize the risk of diabetes-related complications. By integrating DSME with diabetes technology, healthcare providers can ensure that patients derive maximum benefit from these innovations, ultimately enhancing their overall well-being and quality of life.

Conclusion

Technological innovations have transformed the landscape of T1DM management, offering unprecedented opportunities to enhance patient care and outcomes. Continuous glucose monitoring systems, Hybrid/closed-loop insulin delivery systems, connected insulin pens, smartphone applications, digital healthcare platforms and artificial intelligence in technology have revolutionized glycemic control, treatment adherence, and patient engagement. These advancements provide personalized, data-driven approaches to diabetes management, empowering individuals with T1DM to make informed decisions about their health and lifestyle with much safety and efficacy. While challenges such as cost, technical issues, and user acceptance remain, the rapid pace of innovation in this field promises further enhancements in precision, effectiveness, and user-friendliness. Overall, technological innovations offer a promising pathway towards improving the quality of life for individuals living with T1DM and reducing the burden of this chronic condition on healthcare systems and society as a whole.

References

1. Mobasser M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojaziadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. *Health Promot Perspect*. 2020 Mar 30;10(2):98-115.
2. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabetes Endocrinol*. 2022 Oct;10(10):741-760.
3. Zimmerman C, Albanese-O'Neill A, Haller MJ. Advances in Type 1 Diabetes Technology Over the Last Decade. *Eur Endocrinol*. 2019 Aug;15(2):70-76.
4. Beck RW, Riddlesworth T, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 1 diabetes receiving multiple daily insulin injections: a randomized trial. *Ann Intern Med*. 2017;167(6):365-374.
5. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. *N Engl J Med*. 2019;381(18):1707-1717.
6. Abraham O, Feingold-Link L, Adler G, et al. Efficacy and Safety of a Prescription Digital Therapeutic as an Adjunct to Insulin Therapy in Patients With Type 1 Diabetes: Results of a Randomized Controlled Trial. *Diabetes Care*. 2020;43(5):1130-1136.
7. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603.
8. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. *Diabetes Care*. 2018;41(11):2370-2376.
9. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients With Diabetes. *Diabetes Technol Ther*. 2019;21(2):81-85.
10. Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. *Diabetes Care*. 2018;41(11):2275-2280.
11. Rodbard D. Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy. *Diabetes Obes Metab*. 2023 Feb;25(2):596-601.
12. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *JAMA*. 2017;317(4):371-378.
13. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. *Diabetes Care*. 2012;35(1):32-38.
14. Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. Accuracy of Flash Glucose Monitoring and Continuous Glucose Monitoring technologies: Implications for Clinical Practice. *Diab Vasc Dis Res*. 2018;15(3):175-184.
15. Beck RW, Bergenstal RM, Cheng P, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. *J Diabetes Sci Technol*. 2019;13(4):614-626.
16. Adolfsson P. The use of insulin pumps in children, adolescents, and adults: a review of the literature. *Pediatr Diabetes*. 2014;15 Suppl 20:84-91.
17. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. *N Engl J Med*. 2012;366(17):1616-1624.
18. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. *Cochrane Database Syst Rev*. 2010;(1):CD005103.
19. Rubin RR, Peyrot M. Quality of life and diabetes. *Diabetes Metab Res Rev*. 1999;15(3):205-218.

20. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. *JAMA*. 2016;316(13):1407-1408.
21. Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. *Diabetes Care*. 2017;40(6):764-770.
22. Thabit H, Tauschmann M, Allen JM, et al. Home Use of an Artificial Beta Cell in Type 1 Diabetes. *N Engl J Med*. 2015;373(22):2129-2140.
23. Breton, M.D., Kanapka, L.G., Beck, R.W. et al. "A Randomized Trial of Closed-Loop Control in Type 1 Diabetes." *N Engl J Med* 2020; 383: 836–845
24. Bergenstal, R.M., Garg, S., Weinzimer, S.A. et al. "Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients with Type 1 Diabetes." *JAMA* 2020; 323:1355–1366
25. Benhamou, P.Y., Franc, S., Reznik, Y. et al. "Closed-Loop Insulin Delivery in Suboptimally Controlled Type 1 Diabetes: A Multicentre, 12-Week Randomised Trial." *Lancet* 2018;392: 1321–1329.
26. Lewis, D., Leibrand, S., Real-world use of the CamAPS FX closed-loop system in children and adolescents with type 1 diabetes. *Pediatric Diabetes*, 2021;22: 257-264.
27. Brown SA, Basu A, Kovatchev BP. Artificial pancreas technology: current progress and future prospects. *Diabetes Manag (Lond)*. 2021;11(4):313-330.
28. Lajara R, Fetchick DA, Morris TL, Nikkel C, Huang JC, Matfin G. Improved glycemic control with connected insulin pens: a randomized controlled trial. *J Med Econ*. 2020;23(11):1352-1358.
29. Reutrakul S, Chirakalwasan N. Connected insulin pens: Real-world evidence and opportunities. *J Diabetes Investig*. 2021;12(1):1-4.
30. Rossi MC, Nicolucci A, Lucisano G, et al. Impact of the "Diabetes Interactive Diary" telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. *Diabetes Technol Ther*. 2013;15(8):670-679.
31. Placzekiewicz-Jankowska E, Krochak M, Odrobina D, Cyganek K, Wojtusik J, Malecki MT. Assessment of the usefulness of mobile applications for patients with type 1 diabetes: a randomized controlled trial. *J Clin Med*. 2020;9(5):1567. doi:10.3390/jcm9051567
32. Vallon C, Köberich S, von Klüchtzner K, et al. Evaluation of a mobile phone-based intervention to increase parents' knowledge about the measles-mumps-rubella vaccination and their psychological empowerment: mixed-methods study. *JMIR Mhealth Uhealth*. 2021;9(4):e24413. doi:10.2196/24413
33. Tanenbaum ML, Adams RN, Hanes SJ, et al. Optimal use of diabetes devices: Clinician perspectives on barriers and adherence to device use. *J Diabetes Sci Technol*. 2017;11 -33
34. Kebede MM, Liedtke TP, Möllmann J, et al. Artificial intelligence predicts the need for insulin therapy in outpatients with type 2 diabetes mellitus. *J Diabetes Sci Technol*. 2021;15(2):389-395.
35. Steck AK, Vehik K, Bonifacio E, et al. Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). *Diabetes Care*. 2015;38(5):808-813. doi:10.2337/dc14-2462
36. Steinhubl SR, Muse ED, Topol EJ. Can mobile health technologies transform health care? *JAMA*. 2013;310(22):2395-2396.